Rabbit-immunoglobulin G levels in patients receiving thymoglobulin as part of conditioning before unrelated donor stem cell transplantation.
OBJECTIVE
The role of serum concentrations of rabbit antithymoglobulin (ATG) in the development of acute graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT) with unrelated donors is unknown.


METHODS
We determined the serum concentration of rabbit immunoglobulin-G (IgG) using an enzyme linked immunosorbent assay in 61 patients after unrelated donor HSCT. The doses of ATG ranged between 4 and 10 mg/kg. The conditioning consisted mainly of cyclophosphamide and total body irradiation or busulfan. Most patients received GVHD prophylaxis with cyclosporine and methotrexate.


RESULTS
The rabbit IgG levels varied widely in each dose group. The levels of rabbit IgG gradually declined and could still be detected up to five weeks after HSCT. We found a correlation between the grade of acute GVHD and the concentration of rabbit IgG in serum before the transplantation (p=0.017). Patients with serum levels of rabbit IgG >70 mg/mL before HSCT ran a very low risk of developing acute GVHD grades II-IV, as compared to those with levels <70 mg/mL (11% vs. 48%, p=0.006).


CONCLUSIONS
The measurement of rabbit IgG levels in patients receiving ATG as prophylaxis against GVHD after HSCT may be of value in lowering the risk of severe GVHD.
Remberger
Mats
M
Department of Clinical Immunology, Center for Allogeneic Stem Cell Transplantation, Karolinska Institutet, Karolinska University Hospital, SE-141 86 Stockholm, Sweden. mats.remberger@labmed.ki.se <mats.remberger@labmed.ki.se >
Sundberg
Berit
B
D000293:Adolescent; D000328:Adult; D000818:Animals; D000911:Antibodies, Monoclonal / Q000378:metabolism*; D000961:Antilymphocyte Serum / Q000378:metabolism*; D002066:Busulfan / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D003520:Cyclophosphamide / Q000627:therapeutic use; D005260:Female; D006086:Graft vs Host Disease / Q000517:prevention & control / Q000628:therapy; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood*; D007223:Infant; D008297:Male; D008875:Middle Aged; D011817:Rabbits; D033581:Stem Cell Transplantation / Q000379:methods*; D019172:Transplantation Conditioning; D014916:Whole-Body Irradiation / Q000379:methods
D000911:Antibodies, Monoclonal; D000961:Antilymphocyte Serum; D007074:Immunoglobulin G; D003520:Cyclophosphamide; C512542:thymoglobulin; D002066:Busulfan